Doc Logic,
You’re absolutely right, the UK’s “Specials” framework has traditionally been reserved for therapies with some level of established safety, often from Phase 3 trials or equivalent data. That understanding has guided its use for years.
What’s changed more recently is the formal expansion of this framework to include Advanced Therapy Medicinal Products (ATMPs) under Statutory Instrument 2025 No. 87, which was specifically introduced to accommodate personalized, cell-based treatments like autologous dendritic cell vaccines.
Here’s what the updated framework now allows:
1. Use of patient-specific ATMPs without full MHRA marketing authorization, provided that:
• Each dose is made for a named patient;
• A UK physician has prescribed it;
• Manufacturing takes place in a licensed GMP facility.
2. Decentralized manufacturing under a Control Site License, allowing technologies like Flaskworks to operate across multiple sites under centralized oversight.
3. Cross-border logistics: Tumor tissue or leukapheresis material can be imported into the UK, the therapy manufactured locally, and the final product exported back to the patient’s treating provider, no need for patient travel.
4. Combination therapies are allowed as long as all components are prescribed for the same named patient (e.g., a vaccine paired with Poly-ICLC or another immune modulator).
5. Batch production for repeat dosing: The framework permits cryopreserved, multi-dose batches to be prepared and delivered over time, which aligns well with how dendritic cell vaccines are typically administered.
This expansion was deliberate, designed to enable controlled access to cell-based therapies with evidence of safety and potential benefit, even before full approval.
Thanks for raising this, it’s important we’re all working from the most current framework as this field evolves.
(Ref: UK Statutory Instrument 2025 No. 87 gov.uk)
Best regards
Bullish
Market Data 
Markets 
AI
